Bulbar palsy in multiple myeloma

Haematologica. 2005 Dec;90(12 Suppl):ECR42.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bone Marrow Transplantation / adverse effects
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Bulbar Palsy, Progressive / etiology*
  • Bulbar Palsy, Progressive / pathology
  • Combined Modality Therapy
  • Cranial Fossa, Posterior / pathology*
  • Cranial Nerve Diseases / etiology
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Doxorubicin / administration & dosage
  • Fatal Outcome
  • Female
  • Graft vs Host Disease / etiology
  • Humans
  • Immunocompromised Host
  • Immunoglobulin Light Chains / blood
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use
  • Magnetic Resonance Imaging
  • Methylprednisolone / adverse effects
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Multiple Myeloma / complications*
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / pathology
  • Multiple Myeloma / surgery
  • Myeloma Proteins / analysis
  • Pneumonia, Aspiration / etiology
  • Pyrazines / therapeutic use
  • Reflex, Abnormal
  • Transplantation, Homologous / adverse effects
  • Vincristine / administration & dosage

Substances

  • Boronic Acids
  • Immunoglobulin Light Chains
  • Immunosuppressive Agents
  • Myeloma Proteins
  • Pyrazines
  • Vincristine
  • Bortezomib
  • Dexamethasone
  • Doxorubicin
  • Cyclosporine
  • Methylprednisolone

Supplementary concepts

  • VAD protocol